-
Mashup Score: 6Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study - 2 year(s) ago
The phase III ASPEN study demonstrated the comparable efficacy and improved safety of zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia (WM). Here, we report long-term follow-up outcomes from ASPEN. The primary end point was the sum of very good partial response (VGPR) + complete response (CR) rates; secondary and exploratory end points were also reported. Cohort 1 comprised 201 patients (myeloid differentiation primary response 88–mutant WM: 102 receiving zanubrutinib; 99 receiving ibrutinib); cohort 2 comprised 28 patients (myeloid differentiation primary response 88 wild-type WM: 28 zanubrutinib; 26 efficacy evaluable). At 44.4-month median follow-up, VGPR + CR rates were 36.3% with zanubrutinib versus 25.3% with ibrutinib in cohort 1 and 30.8% with one CR in cohort 2. In patients with CXC motif chemokine receptor 4 mutation, VGPR + CR rates were 21.2% with zanubrutinib versus 10.0% with ibrutinib (cohort 1). Median progression-free survival and overall su
Source: ascopubs.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 7Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma - 2 year(s) ago
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. Immune checkpoint inhibitors have led to unprecedented prolongation of overall survival (OS) for patients with advanced melanoma. Five-year follow-up of KEYNOTE-006 showed pembrolizumab prolonged survival versus ipilimumab. Efficacy results with 7-year follow-up are presented. At data cutoff (April 19, 2021), median follow-up was 85.3 months (range, 0.03-90.8 months). Median OS was 32.7 months for pembrolizumab versus 15.9 months for ipilimumab (hazard ratio [HR], 0.70; 95% CI, 0.58 to 0.83); 7-year OS was 37.8% and 25.3%, respectively. OS HRs favored pembrolizumab regar
Source: ascopubs.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
✨ #JCO #ClinicalTrialUpdates: Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced #Melanoma ➡️ https://t.co/dUwZJZxvBV #melsm https://t.co/L44JB5Slhw
-
-
Mashup Score: 6
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has…
Source: Journal of Clinical OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
✨ #JCO #ClinicalTrialUpdates: 10-year AMAROS results confirm safety of axillary #radiotherapy for sentinel node positive #BreastCancer. https://t.co/x9FdPaizxs #BCSM #radonc @EORTC_BCG
-
-
Mashup Score: 0
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has…
Source: Journal of Clinical OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
✨#JCO #ClinicalTrialUpdates: SOPHIA: No difference in overall survival between margetuximab vs trastuzumab in patients w/ previously treated HER2➕ advanced #BreastCancer 👉 https://t.co/s8LwjLYWoD #BCSM @hoperugo https://t.co/f0ecVZRtvS
-
-
Mashup Score: 1
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co‐primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has…
Source: Journal of Clinical OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
✨ #JCO #ClinicalTrialUpdates: Genomic alterations acquired by anti-EGFR-Ab resistant metastatic #ColorectalCancer in later lines are rare with upfront anti-EGFR-Chemo Rx. #CRCSM @kanwal_raghav @skopetz https://t.co/qbxpbFrInQ https://t.co/56vNocraET
-
-
Mashup Score: 3
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has…
Source: Journal of Clinical OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
✨ #JCO #ClinicalTrialUpdates: EVAN Study Updated overall survival and exploratory analysis erlotinib vs vinorelbine + cisplatin in stage IIIA EGFR+ non-small cell #LungCancer ➡️ https://t.co/hzyGYy829g #LCSM #NSCLC https://t.co/C2QXEW9S1s
-
-
Mashup Score: 6
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co‐primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has…
Source: Journal of Clinical OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
✨ #JCO #ClinicalTrialUpdates: PACE-MDS Study ➡️ Luspatercept demonstrates long-term safety & efficacy for treatment of #anemia in patients w/ lower-risk #myelodysplastic syndrome. Read more: https://t.co/hnx5zI9xjn #MDS #mpnsm @UwePlatzbecker @AGiagounidis https://t.co/Nb5abYbXZc
-
-
Mashup Score: 1
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned coprimary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has…
Source: Journal of Clinical OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
✨ #JCO #ClinicalTrialUpdates: ☢️ Intensity-modulated radiation therapy reduces patient-reported chronic toxicity compared to conventional pelvic radiation therapy in #EndometrialCancer ➡️ https://t.co/jeWOCSGby1 #gyncsm #radonc https://t.co/ifNQpi8g9z
-
-
Mashup Score: 0
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned coprimary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has…
Source: Journal of Clinical OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
✨ #JCO #ClinicalTrialUpdates: Six-Year Results from RELEVANCE: Lenalidomide + rituximab (R2) vs rituximab + chemotherapy followed by rituximab maintenance in untreated advanced #FollicularLymphoma 👉 https://t.co/hrFYpmyTdR #lymsm https://t.co/0v9QJM3UCK
-
-
Mashup Score: 8Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated EGFR - 3 year(s) ago
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned coprimary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has…
Source: Journal of Clinical OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
✨ #JCO #ClinicalTrialUpdates: NEJ009: EGFR-TKI+chemotherapy improves progression free survival and PFS2 in pts with EGFR-mutated non small cell #LungCancer 👉 https://t.co/IxvyPNIP9L #NSCLC #LCSM https://t.co/PLhudPkQFp
-
✨ #JCO #ClinicalTrialUpdates: Zanubrutinib continues to demonstrate meaningful efficacy and favorable safety in patients with #WaldenströmMacroglobulinemia 👉 https://t.co/NySi1ibcAL #lymsm @thanosdimop https://t.co/2tv0WNCjGD